Biden Admin Proposes Add-On Pay To Promote Sickle Cell Rx Access

CMS is proposing a policy to boost the New Technology Add-on Payment (NTAP) to hospitals for gene therapies intended to treat sickle cell disease, a move Bloomberg health analyst Duane Wright says could benefit drug makers and hospitals in addition to patients and would be consistent with a separate administration proposal to improve access and utilization to expensive cell and gene therapies in Medicaid. CMS’ proposed inpatient hospital payment rule for fiscal 2025 includes a proposal to increase the NTAP...